Gentherm Inc

Gentherm announced it received FDA 510(k) clearance for its patented ThermAffyx™ Patient Safety System, a Class II medical device. This system integrates active patient warming, securement, and pressure reduction into a single platform for robotic-assisted surgical procedures. Product trials are set to begin in August, with revenue generation anticipated to start in Q3 2026, significantly expanding the company's medical product offerings.

Gentherm Inc. announced it will release its financial results for the second quarter of 2026 on Thursday, July 23, 2026. The company will host a conference call and webcast on the same day at 8 am ET to discuss these results. Details for accessing the call and webcast, including dial-in numbers and replay information, were provided.

Gentherm Inc. and its subsidiaries have entered into a Third Amended and Restated Credit Agreement, establishing a new $550 million secured five-year revolving credit facility. This facility replaces the previous agreement, enhancing the company's financial flexibility and liquidity. The agreement includes customary covenants and guarantees from both US and German subsidiaries, with interest rates and fees tied to the company's consolidated net leverage ratio.

Gentherm announced its participation in three upcoming investor conferences in June 2026. President and CEO Bill Presley and Executive Vice President of Finance, CFO, and Treasurer Jon Douyard will host a fireside chat at the Baird Global Consumer, Technology & Services Conference on June 3, which will be webcast. The company will also attend the Stifel Cross Sector 1x1 Conference on June 2 and the Wells Fargo Industrials & Materials Conference on June 9.

Gentherm Inc. shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing the maximum number of shares available for issuance by 1,700,000. This decision was made at the annual meeting on May 14, 2026, where shareholders also elected nine directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026. All proposals presented at the meeting received shareholder approval.

Gentherm Incorporated filed an Amendment No. 1 to its Current Report on Form 8-K, originally filed on February 27, 2026. The sole purpose of this amendment is to correct a clerical error regarding the signatory for Gentherm (Texas), Inc. on the First Amendment to the Second Amended and Restated Credit Agreement. No other changes were made to the original report or the terms of the credit agreement amendment.

Gentherm Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026. The company confirmed it is a large accelerated filer and has filed all required reports. As of April 17, 2026, there were 30,667,290 shares of common stock issued and outstanding.

Gentherm Incorporated publicly announced its financial results for the first quarter of 2026 on April 23, 2026. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss these results. Supplemental materials for the conference call can be accessed on the Investors section of Gentherm's website.

Gentherm reported strong first-quarter 2026 financial results, achieving record quarterly revenue of $394 million, an 11.3% increase year-over-year. The company saw significant improvement in profitability, with adjusted diluted EPS rising to $0.84 from $0.51 in the prior year and gross margin expanding to 24.7%. Gentherm also announced progress on its transformational combination with Modine Performance Technologies, which is on track to close by year-end, and submitted a 510(k) premarket notification for its ThermAffyx™ Patient Safety System to the FDA.